Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Posts Flat Revenue Growth in Q3; Life Sciences Arm Inches Higher

NEW YORK, Oct. 23 (GenomeWeb News) - PerkinElmer today said that third-quarter sales remained largely flat, though revenue from its life and analytical-sciences business increased slightly in the period.

 

Total revenue for the three months ended Sept. 28 was $367 million compared with $366 million in the same period one year ago. Receipts from the life and ananlytical-sciences unit inched up to $235 million from $232 million during the third quarter 2002, the company said.

 

Companywide R&D spending was also flat in the third quarter, reaching $20 million from $20.5 million year over year.

 

However, net income doubled in the current quarter to $14.3 million, or $.11 per share, from $7 million, or $.06 per share, in the same quarter last year.

 

PerkinElmer said it had around $141 million in cash and cash equivalents as of Sept. 29.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.